HiRO完成收購美國臨床研究組織Courante Oncology,持續拓展全球佈局和運營能力
廠商名稱:賀維斯特國際醫藥有限公司
發佈日期:2025-05-12
攤位號碼:M435
Aug. 31, 2023 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), an innovation global CRO, is pleased to announce the successful acquisition of Courante Oncology, a US-based full-service clinical research provider specializing in oncology product development.
As a reputable boutique CRO with a strong track record of delivering high-quality, expedited clinical trials in the Asia-Pacific, HiRO's acquisition of Courante Oncology marks a significant milestone in its global expansion. This strategic move further strengthens HiRO's capabilities in managing global studies, extending its presence into the US market.
Courante Oncology brings over 25 years of invaluable experience in the drug development industry. The company's expertise spans all aspects of phase 1-3 clinical trials, ranging from initial feasibility studies and protocol development to site monitoring and closeout visits. Renowned for their dedicated commitment to oncology research and clinical trial management, the Courante team has earned a remarkable reputation in the industry.
The synergy between HiRO and Courante Oncology creates a powerful partnership that will deliver successful clinical trials tailored to meet the evolving needs of the industry. Both companies possess robust clinical research networks, covering the Asia-Pacific region and the US, ensuring a seamless integration of expertise and resources.
"We are thrilled to welcome Courante Oncology into the HiRO family," said Dr. Karen Chu, Founder and CEO of HiRO. "This acquisition allows us to leverage Courante's extensive experience in oncology trials and enhance our capabilities in managing global studies. Together, we strive to deliver best-in-class cross-border solutions and relentless accountability that set us apart in the demanding clinical trial landscape. Our focus remains on accelerating the delivery of innovative medicines with simple, rapid, cost-effective clinical research solutions across the commercialization pathway."
"This marks an exciting chapter for Courante as we join forces with HiRO," said Sheri Smith, President of Courante Oncology. "We are excited to join the HiRO family and collaborate closely with their team. This integration will enable us to further expand our service offerings and functions into the US and beyond. We look forward to collaborating with our clients, to deliver effective, streamlined clinical trial solutions that meet and exceed their expectations."
The acquisition of Courante Oncology represents a significant step forward for HiRO as it continues to solidify its position as a global CRO. With a strengthened presence in the US and expanded capabilities, HiRO is well-positioned to deliver innovative and expedited clinical trial solutions to its clients worldwide.
About HiRO:
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integration capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
About Courante Oncology:
Courante Oncology is a full-service clinical research provider specializing in oncology product development. The company offers a wide range of clinical trial management and support services to the pharmaceutical and medical device industries, including project management, clinical site monitoring, quality assurance, and medical writing services.
Courante Oncology believes the challenges of oncology clinical trials require a research team that is uniquely experienced and trained. The strength of Courante Oncology lies in the team's collective experience and ability to adapt to clients' specific research needs. For more information on Courante Oncology, please visit www.couranteoncology.com.
Media Contact:
info@harvestiro.com
更多參展商新聞稿
- 研討會 日本食品分析中心 / 2025-07-01
- 精密微流道模仁 微米結構電鑄/金屬模仁解決方案 和淞科技股份有限公司 / 2025-07-01
- 具有ISO13485品質管理系統 致力打造醫療級噴霧片 和淞科技股份有限公司 / 2025-07-01
- ESG環保優選 微孔霧化片 和淞科技股份有限公司 / 2025-07-01
- 報名國鼎新藥研討會: "推進Antroquinonol全球三期臨床:在轉移性胰臟癌的第1線治療" 國鼎生物科技股份有限公司 / 2025-06-30
- 最快、最安全的深層過濾 瑞士商力威磁浮技術有限公司 台灣分公司 / 2025-06-30
- 灌注培養中最高細胞活性 瑞士商力威磁浮技術有限公司 台灣分公司 / 2025-06-30
- 下一代療法製造 瑞士商力威磁浮技術有限公司 台灣分公司 / 2025-06-30
- 突破性幹細胞療法!鴻曜醫學MiSaver ⼼肌梗塞後修復效果顯著 鴻曜醫學股份有限公司 / 2025-06-27
- 暢鴻生物提供您更有效率的產品與方案 暢鴻生物科技股份有限公司 / 2025-06-27
- 日本兩位細胞製造權威現身,聚焦《QbD實現的PAT》與《細胞製造中的QbD實踐與製程設計策略》 宏騏實業股份有限公司 / 2025-06-27
- 現場校正、抽檢應用 攜帶式測量儀 幸託有限公司 / 2025-06-27
- THERMAX 溫度貼紙,使用顏色變化來提供溫度的視覺指示,通過標準解決大多數溫度測量問題 幸託有限公司 / 2025-06-27
- 精睿與您相約 2025 BIO Asia-Taiwan 展覽會 精睿醫藥科技股份有限公司 / 2025-06-26
- EffPha – 由專家領軍的CRO,為您的藥物開發提供全方位支持 精睿醫藥科技股份有限公司 / 2025-06-26
- 富田永續生醫科技發表創新脂質奈米粒子平台,助攻 API 高效吸收,推動藥品與保健品劑型革新。 富田永續生醫科技股份有限公司 / 2025-06-26
- 次世代 API中間體合成服務與智慧品保平台正式亮相,富田永續生醫引領製藥產線邁向高效率、智慧化新紀元 富田永續生醫科技股份有限公司 / 2025-06-26
- 神脂體™|醫美品牌的助攻神器,顛覆神經醯胺應用極限!富田永續生醫為美妝品牌打造全新可能性 富田永續生醫科技股份有限公司 / 2025-06-26
- 汎球生物藥劑布局功能性活性材料 打造生技美妝應用新藍海 汎球生物藥劑研發股份有限公司 / 2025-06-25
- 國璽搶攻超高齡+再生雙法商機 腦中風細胞新藥拚提早上市 國璽幹細胞應用技術股份有限公司 / 2025-06-25